RCKT vs. RCUS, DRNA, AUPH, HRTX, YMAB, ASND, CERE, LEGN, ITCI, and VKTX
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Arcus Biosciences (RCUS), Dicerna Pharmaceuticals (DRNA), Aurinia Pharmaceuticals (AUPH), Heron Therapeutics (HRTX), Y-mAbs Therapeutics (YMAB), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Legend Biotech (LEGN), Intra-Cellular Therapies (ITCI), and Viking Therapeutics (VKTX). These companies are all part of the "medical" sector.
Arcus Biosciences (NYSE:RCUS) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by insiders. Comparatively, 31.1% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Arcus Biosciences presently has a consensus price target of $40.50, indicating a potential upside of 161.29%. Rocket Pharmaceuticals has a consensus price target of $52.13, indicating a potential upside of 129.83%. Given Rocket Pharmaceuticals' higher probable upside, research analysts clearly believe Arcus Biosciences is more favorable than Rocket Pharmaceuticals.
Arcus Biosciences has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 11 mentions for Rocket Pharmaceuticals and 10 mentions for Arcus Biosciences. Rocket Pharmaceuticals' average media sentiment score of 0.70 beat Arcus Biosciences' score of 0.29 indicating that Arcus Biosciences is being referred to more favorably in the media.
Rocket Pharmaceuticals received 189 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 72.23% of users gave Rocket Pharmaceuticals an outperform vote while only 64.66% of users gave Arcus Biosciences an outperform vote.
Rocket Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
Rocket Pharmaceuticals has a net margin of 0.00% compared to Rocket Pharmaceuticals' net margin of -97.47%. Rocket Pharmaceuticals' return on equity of -40.98% beat Arcus Biosciences' return on equity.
Summary
Rocket Pharmaceuticals beats Arcus Biosciences on 11 of the 17 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
